277 related articles for article (PubMed ID: 20167130)
1. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks.
Tabu K; Kimura T; Sasai K; Wang L; Bizen N; Nishihara H; Taga T; Tanaka S
Mol Cancer; 2010 Feb; 9():39. PubMed ID: 20167130
[TBL] [Abstract][Full Text] [Related]
2. hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors.
Ohnishi S; Maehara O; Nakagawa K; Kameya A; Otaki K; Fujita H; Higashi R; Takagi K; Asaka M; Sakamoto N; Kobayashi M; Takeda H
PLoS One; 2013; 8(6):e66255. PubMed ID: 23840432
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation.
Gopisetty G; Xu J; Sampath D; Colman H; Puduvalli VK
Oncogene; 2013 Jun; 32(26):3119-29. PubMed ID: 22945648
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells.
Dong L; Qi N; Ge RM; Cao CL; Lan F; Shen L
Neurosci Lett; 2010 Nov; 484(3):210-4. PubMed ID: 20800650
[TBL] [Abstract][Full Text] [Related]
5. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
6. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
7. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP
Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.
Friel AM; Zhang L; Curley MD; Therrien VA; Sergent PA; Belden SE; Borger DR; Mohapatra G; Zukerberg LR; Foster R; Rueda BR
Reprod Biol Endocrinol; 2010 Dec; 8():147. PubMed ID: 21122138
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2.
Iida H; Suzuki M; Goitsuka R; Ueno H
Int J Oncol; 2012 Jan; 40(1):71-9. PubMed ID: 21947321
[TBL] [Abstract][Full Text] [Related]
11. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
Lai CY; Schwartz BE; Hsu MY
Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
[TBL] [Abstract][Full Text] [Related]
12. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
13. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
14. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics.
Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y
Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969
[TBL] [Abstract][Full Text] [Related]
15. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
[TBL] [Abstract][Full Text] [Related]
16. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis.
Ding W; Mouzaki M; You H; Laird JC; Mato J; Lu SC; Rountree CB
Hepatology; 2009 Apr; 49(4):1277-86. PubMed ID: 19115422
[TBL] [Abstract][Full Text] [Related]
17. CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.
Feng BH; Liu AG; Gu WG; Deng L; Cheng XG; Tong TJ; Zhang HZ
Oncol Rep; 2013 Aug; 30(2):815-23. PubMed ID: 23708735
[TBL] [Abstract][Full Text] [Related]
18. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
